Synopsis Drugs used in Myasthenia Gravis (MG) have limitations for use due to symptomatic effect which could induce remission, adverse effects, delayed therapeutic outcomes, or lack of safety and efficacy data. Thus, an immunosuppressive agent with a quick onset and less serious side effects is needed for treating MG, especially for those Osserman grade III & IV MG. The present study evaluates the efficacy and safety of tacrolimus in Osserman grade III and IV MG patients. This week’s “ MED FACT ” discusses a cohort study from Clinical Neurology and Neurosurgery, “ Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis ”. Authors: L.
Zhao et. al. Key Takeaways Tacrolimus is an effective and safe treatment option for Osserman grade III & IV MG patients. Objective: The present study evaluates the efficacy and safety of tacrolimus in Osserman grade…
